Table 2.
Clinical courses of patients receiving genetic alteration-driven therapies. PFS for molecular-directed therapy is calculated as months until data cut-off (31.12.2022)
| Cancer type, tumor stage at time of molecular-directed therapy |
Genetic alteration | Drug | Lines of pretreatments (n) | Time on prior therapy (months) | PFS for molecular-directed therapy (months) | Best response |
|---|---|---|---|---|---|---|
|
CCC, UICC IV |
IDH1 R132C |
Ivosidenib | 1 | 12.4 | 2.5 | progress |
|
CCC, UICC IV |
IDH1 R132C |
Ivosidenib | 3 | 11.4 | 2.3 | stable disease |
|
CCC, UICC IV |
ERBB3 G284R |
Lapatinib + Trastuzumab | 2 | 10.3 | 7.3 (ongoing) | mixed response |
|
CCC, UICC IV |
dMMR | Pembrolizumab | 1 | 3.7 | 65.1 (ongoing) | complete response |
|
CRC, UICC IV |
dMMR/ BRAF V600E |
Pembrolizumab/ Encorafenib + Cetuximab | 0 | 0 | 12.2 (9.2/3.0) | stable disease/ progress |
|
CRC, UICC IV |
dMMR/ BRAF V600E | Pembrolizumab | 0 | 0 | 15.5 (ongoing) | stable disease |
|
CRC, UICC IV |
dMMR |
Pembrolizumab/ Nivolumab + Ipilimumab |
0 | 0 | 28.8 (27.6/1.2) | partial response/ n.a. |
|
CRC, UICC IV |
BRAF V600E |
Encorafenib + Binimetinib + Cetuximab |
1 | 1.4 | 5.1 | partial response |
|
CRC, UICC IV |
dMMR | Pembrolizumab | 0 | 0 | 8.9 | mixed response |
|
CRC, UICC IV |
BRAF V600E | Encorafenib + Cetuximab | 0 | 0 | 3.8 | mixed response |
|
CRC, UICC IV |
BRAF V600E | Encorafenib + Cetuximab | 0 | 0 | 0.8 (ongoing) | Not assessed (ongoing) |
|
Duodenal adenocarcinoma, UICC IV |
dMMR | Pembrolizumab/ Nivolumab | 1 | 3 | 39.6 (36.3/3.3) | stable disease |
|
PDAC, UICC IV |
BRCA1 E1161Ffs*3/ BRCA2 S497L |
Olaparib | 3 | 19.3 | 9.0 (ongoing) | Partial response |
CCC Cholangiocellular carcinoma, CRC colorectal cancer, PDAC pancreatic ductal adenocarcinoma, dMMR deficient mismatch repair, ND not discussed (cases were not presented in local molecular tumor board), UICC Union for International Cancer Control tumor stage